In addition to the comments above, it is worth observing that preliminary prospective data addressing this question was presented at AACR this year by @Kim Reiss Binder. Her group is evaluating the role of rucaparib maintenance for patients with either germline or somatic BRCA or PALB2 mutation...

I have been using olaparib as an off-label maintenance strategy for patients with germline mutations in dsDNA repair proteins. And, as a side-note, we have an ongoing trial at DFCI for niraparib for patients with germline or somatic alterations in dsDNA repair genes that extend beyond just BRCA1/2.T...

A recent retrospective study published in the Oncologist enrolled both patients with somatic and germline mutations in DNA repair pathway proteins and while the study was small (only 13 patients), the response rates were reported at 23%. We need more dedicated clinical trial data on the specific res...

Definitely yes. However, it is infrequent to find a situation where one would stop FOLFIRINOX if the patient continues to respond. More likely, would use in situation where a patient would require a treatment break because of toxicity. Previously, would increase interval between treatments.